Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
Major pharmaceutical multinationals are looking to collaborate with Indian drug firms, leveraging their cost-efficient manufacturing capabilities, robust supply chains, and innovative research potential. 31 July 2024
The Russian government will be ready to significantly increase state procurements of drugs against hepatitis C in case of reduction price for them both by global drugmakers and Russian pharmaceutical companies. 31 July 2024
Although drug sales in Russia fell 13% in the first four months of the current year in volume terms to 1.7 billion packages, they grew by 4.8% to 390 billion roubles ($5.4 billion) in terms of value, reports The Pharma Letter’s local correspondent. 15 June 2021
The adjectives that accompanied the US approval of the first drug to treat Alzheimer’s disease in nearly two decades sought to sum up the apparent magnitude of the moment. 8 June 2021
Leading Russian pharmaceutical producers and foreign companies operating in the local market have called on the national government to increase the volume of support for companies that are involved in the development and launch of innovative drugs in the domestic market, The Pharma Letter’s local correspondent reports. 8 June 2021
An Expert View from Mark Doyle, co-founder of UK company The Method and creator of A Life in a Day experience, which seeks to support the pharmaceutical and healthcare industries in developing patient-centric strategies for more impactful engagement. 7 June 2021
The Russian Parliament (State Duma) has finally approved legislation that allows the production of original drugs intended for exports without the permission of a patent holder, according to recent statements by the press-service of the Duma and some local media, reports The Pharma Letter’s local correspondent 1 June 2021
A sharp rise in the price of raw material of key drugs used in the treatment of COVID-19, as well as other active pharmaceutical ingredients (API) over the last few weeks, has unnerved Indian drug manufacturers. 1 June 2021
The annual meeting of the American Society of Clinical Oncology (ASCO) kicks off online on June 4, with more than 2,500 abstract presentations representing cutting-edge research from around the world. 28 May 2021
A new Russian vaccine against COVID-19 and influenza is being developed at Natsimbio, a subsidiary of the Russian state corporation Rostec, according to recent statements by sources close to the company and local analysts. 25 May 2021
The Russian government will use the mechanism of interventions in the domestic pharmaceutical market to tighten control of drug prices, according to recent statements by some senior state officials and local media, reports The Pharma Letter’s local correspondent. 25 May 2021
The US Food and Drug Administration strictly prohibits the distribution of counterfeit, diverted, subpotent, substandard, adulterated, misbranded, and expired drugs that pose a serious threat to life. Nevertheless, such drugs continue to end up in circulation, compromising patient safety. 24 May 2021
AJ Ploszay, vice president of digital strategy, IQVIA, provides an Expert View on how the precedent for consumer buying set by companies like Amazon, further accelerated by the digital buying trends driven by COVID-19, are influencing a similar shift in the commercial pharma space. 20 May 2021
US pharma giant Merck & Co’s Russian MSD unit has revoked the registration certificate on its Belsomra (suvorexant) next-generation sleeping pill in Russia, due to the inability of the company to generate sales in the local market, reports The Pharma Letter’s local correspondent. 18 May 2021
The Russian drugmaker R-Pharm will start the production of UK-based AstraZeneca’s COVID-19 vaccine at its facilities in Russia starting in June of the current year, according to recent statements by R-Pharm’s chief executive Vasily Ignatiev, as well as local media, reports the Pharma Letters local correspondent. 18 May 2021
The mere notion of the US government supporting any policies that might encourage pharmaceutical patents to be ignored would have seemed inconceivable only 18 months ago. 17 May 2021
An Expert View from Manjit Singh, chairman of the Pharmaceutical Supply Chain Initiative, which tries to foster responsible supply chains, highlighting the issue of antibiotic resistance and the often-underestimated threat coming from the discharge of material in environment. 14 May 2021
Global insulin producers are losing their positions in the Russian market, due to the active launch of generics by domestic suppliers, according to recent statements by Russian pharmaceutical analysts and local media, reports The Pharma Letter’s local correspondent. 11 May 2021
Catherine Owen, senior vice president of major markets at Bristol Myers Squibb, provides an Expert View on why increasing female representation on corporate boards isn’t just a numbers game. Women bring diverse perspectives that are needed more than ever. 7 May 2021